These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30116027)

  • 21. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
    Noetzel MJ; Rook JM; Vinson PN; Cho HP; Days E; Zhou Y; Rodriguez AL; Lavreysen H; Stauffer SR; Niswender CM; Xiang Z; Daniels JS; Jones CK; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2012 Feb; 81(2):120-33. PubMed ID: 22021324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.
    Garcia-Barrantes PM; Cho HP; Niswender CM; Byers FW; Locuson CW; Blobaum AL; Xiang Z; Rook JM; Conn PJ; Lindsley CW
    J Med Chem; 2015 Oct; 58(20):7959-71. PubMed ID: 26426481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lead optimization of the VU0486321 series of mGlu
    Davis DC; Bungard JD; Chang S; Rodriguez AL; Blobaum AL; Boutaud O; Melancon BJ; Niswender CM; Jeffrey Conn P; Lindsley CW
    Bioorg Med Chem Lett; 2021 Jan; 32():127724. PubMed ID: 33253881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas.
    Gelb T; Pshenichkin S; Rodriguez OC; Hathaway HA; Grajkowska E; DiRaddo JO; Wroblewska B; Yasuda RP; Albanese C; Wolfe BB; Wroblewski JT
    Oncogene; 2015 May; 34(21):2711-20. PubMed ID: 25065592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
    Chan WY; McKinzie DL; Bose S; Mitchell SN; Witkin JM; Thompson RC; Christopoulos A; Lazareno S; Birdsall NJ; Bymaster FP; Felder CC
    Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10978-83. PubMed ID: 18678919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology.
    Muraleetharan A; Wang Y; Rowe MC; Gould A; Gregory KJ; Hellyer SD
    Mol Pharmacol; 2023 Jun; 103(6):325-338. PubMed ID: 36921922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
    Liu F; Grauer S; Kelley C; Navarra R; Graf R; Zhang G; Atkinson PJ; Popiolek M; Wantuch C; Khawaja X; Smith D; Olsen M; Kouranova E; Lai M; Pruthi F; Pulicicchio C; Day M; Gilbert A; Pausch MH; Brandon NJ; Beyer CE; Comery TA; Logue S; Rosenzweig-Lipson S; Marquis KL
    J Pharmacol Exp Ther; 2008 Dec; 327(3):827-39. PubMed ID: 18753411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator.
    Spear N; Gadient RA; Wilkins DE; Do M; Smith JS; Zeller KL; Schroeder P; Zhang M; Arora J; Chhajlani V
    Eur J Pharmacol; 2011 Jun; 659(2-3):146-54. PubMed ID: 21335002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
    Teal LB; Gould RW; Felts AS; Jones CK
    Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors.
    Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).
    Stauffer SR
    ACS Chem Neurosci; 2011 Aug; 2(8):450-70. PubMed ID: 22860171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.
    Stansley BJ; Conn PJ
    Curr Opin Pharmacol; 2018 Feb; 38():31-36. PubMed ID: 29486374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.
    Gould RW; Nedelcovych MT; Gong X; Tsai E; Bubser M; Bridges TM; Wood MR; Duggan ME; Brandon NJ; Dunlop J; Wood MW; Ivarsson M; Noetzel MJ; Daniels JS; Niswender CM; Lindsley CW; Conn PJ; Jones CK
    Neuropharmacology; 2016 Mar; 102():244-53. PubMed ID: 26617071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symmetric signal transduction and negative allosteric modulation of heterodimeric mGlu1/5 receptors.
    Werthmann RC; Tzouros M; Lamerz J; Augustin A; Fritzius T; Trovò L; Stawarski M; Raveh A; Diener C; Fischer C; Gassmann M; Lindemann L; Bettler B
    Neuropharmacology; 2021 Jun; 190():108426. PubMed ID: 33279506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of Phosphorylation of AMPA Glutamate Receptors by Muscarinic M4 Receptors in the Striatum In vivo.
    Mao LM; He N; Jin DZ; Wang JQ
    Neuroscience; 2018 Apr; 375():84-93. PubMed ID: 29432883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia.
    Nair AG; Castro LRV; El Khoury M; Gorgievski V; Giros B; Tzavara ET; Hellgren-Kotaleski J; Vincent P
    Neuropharmacology; 2019 Mar; 146():74-83. PubMed ID: 30468798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.
    Garcia-Barrantes PM; Cho HP; Metts AM; Blobaum AL; Niswender CM; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2016 Feb; 26(3):751-756. PubMed ID: 26778256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia.
    Farrell M; Roth BL
    Neuropsychopharmacology; 2010 Mar; 35(4):851-2. PubMed ID: 20145632
    [No Abstract]   [Full Text] [Related]  

  • 39. mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?
    Dravolina OA; Zvartau E; Danysz W; Bespalov AY
    Psychopharmacology (Berl); 2017 May; 234(9-10):1333-1345. PubMed ID: 28285325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
    Shen W; Plotkin JL; Francardo V; Ko WK; Xie Z; Li Q; Fieblinger T; Wess J; Neubig RR; Lindsley CW; Conn PJ; Greengard P; Bezard E; Cenci MA; Surmeier DJ
    Neuron; 2015 Nov; 88(4):762-73. PubMed ID: 26590347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.